Flagship Ventures Fund IV General Partner LLC
SEC-identified person · CIK 1508051 Identifier-verified
Public-company roles (from insider filings)
| Company | Capacity as filed | Filings |
|---|---|---|
| Evelo Biosciences, Inc. EVLO | Officer | filed 2018 - 2023 |
| Axcella Health Inc. AXLA | Officer | filed 2019 - 2022 |
| Rubius Therapeutics, Inc. RUBY | Director | filed 2018 - 2021 |
| Kaleido Biosciences, Inc. KLDO | Director | filed 2019 - 2021 |
| Seres Therapeutics, Inc. MCRB | Officer | filed 2015 - 2020 |
| Moderna, Inc. MRNA | Director | filed 2018 - 2020 |
| Transmedics Group, Inc. TMDX | Officer | filed 2019 - 2019 |
| Syros Pharmaceuticals, Inc. SYRS | Officer | filed 2016 - 2017 |
| Sesen Bio, Inc. SESN | Officer | filed 2014 - 2016 |
| Editas Medicine, Inc. EDIT | Officer | filed 2016 - 2016 |
| T2 Biosystems, Inc. TTOO | Officer | filed 2014 - 2014 |
All roles under one Commission-assigned identifier - the same person by the SEC's own record, not by name matching. From the SEC's insider-transaction filings (Forms 3, 4 and 5). Every reporting director and officer carries a Commission-assigned identifier (CIK), so these footprints are identifier-verified - no name matching involved. Insiders file when they transact, so dates are filing dates: "last filed" never means "served until". This layer is not yet joined to the nonprofit register - identity joins ship only after independent review.